Holen Sie sich die Stockscreener-App
1.815
4.47%
-0.085
Schlusskurs vom Vortag:
$1.90
Offen:
$1.95
24-Stunden-Volumen:
1.69M
Relative Volume:
0.61
Marktkapitalisierung:
$586.50M
Einnahmen:
$400.57M
Nettoeinkommen (Verlust:
$9.21M
KGV:
45.38
EPS:
0.04
Netto-Cashflow:
$146.36M
1W Leistung:
-5.47%
1M Leistung:
-52.11%
6M Leistung:
-63.70%
1J Leistung:
-88.01%
1-Tages-Spanne:
$1.785
$1.99
1-Wochen-Bereich:
$1.785
$2.08
52-Wochen-Spanne:
$1.59
$15.26
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Firmenname
Ironwood Pharmaceuticals Inc
Sektor
Telefon
617-621-7722
Adresse
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Vergleichen Sie IRWD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
1.815 | 586.50M | 400.57M | 9.21M | 146.36M | 0.04 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-09 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-08-08 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | Eingeleitet | Craig Hallum | Buy |
| 2023-12-14 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-09 | Eingeleitet | Jefferies | Buy |
| 2023-09-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-09-02 | Eingeleitet | CapitalOne | Overweight |
| 2022-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2020-09-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | Eingeleitet | Northland Capital | Outperform |
| 2019-07-10 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-03-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | Hochstufung | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2018-11-07 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-07-23 | Eingeleitet | H.C. Wainwright | Sell |
| 2018-05-09 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2017-07-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2017-05-03 | Eingeleitet | Wells Fargo | Outperform |
| 2017-04-07 | Bestätigt | Mizuho | Buy |
| 2017-02-22 | Bestätigt | Barclays | Equal Weight |
| 2016-11-04 | Bestätigt | Mizuho | Buy |
| 2016-10-24 | Bestätigt | Wedbush | Neutral |
| 2016-10-10 | Bestätigt | Mizuho | Buy |
| 2016-09-27 | Bestätigt | WallachBeth | Hold |
Alle ansehen
Ironwood Pharmaceuticals Inc Aktie (IRWD) Neueste Nachrichten
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Sees Large Growth in Short Interest - MarketBeat
Ironwood Pharmaceuticals Sets Key Date for 2024 Financial ResultsHere's When to Tune In - StockTitan
Ironwood Pharmaceuticals Inc (IRWD): A New Perspective - Stocks Register
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
FY2025 Earnings Forecast for IRWD Issued By Zacks Research - MarketBeat
IRWD Begins Apraglutide NDA Submission, Announces Job Cuts, Stock Falls - MSN
Zacks Research Issues Negative Forecast for IRWD Earnings - MarketBeat
What is Zacks Research’s Estimate for IRWD FY2025 Earnings? - Defense World
Michael Shetzline Sells 41,269 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Stock - MarketBeat
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CEO Sells $244,752.64 in Stock - MarketBeat
Ironwood Pharmaceuticals (IRWD) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Insider Selling: Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Insider Sells 12,048 Shares of Stock - MarketBeat
IRONWOOD PHARMACEUTICALS Earnings Preview: Recent $IRWD Insider Trading, Hedge Fund Activity, and More - Nasdaq
Ironwood Pharmaceuticals CEO Thomas A. McCourt sells $244,752 in stock - MSN
Zacks Research Issues Negative Outlook for IRWD Earnings - Defense World
11,869 Shares in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Acquired by SG Americas Securities LLC - Defense World
Ironwood Pharmaceuticals' principal accounting officer sells $21,204 in stock - MSN
Ironwood Pharmaceuticals' principal accounting officer sells $21,204 in stock By Investing.com - Investing.com Australia
Ironwood Pharmaceuticals CEO Thomas A. McCourt sells $244,752 in stock By Investing.com - Investing.com Australia
Ironwood Pharmaceuticals CFO sells shares worth $21,211 - MSN
Ironwood Pharmaceuticals chief legal officer sells shares worth $68,530 - MSN
Ironwood Pharmaceuticals chief legal officer sells shares worth $68,530 By Investing.com - Investing.com Nigeria
Ironwood Pharmaceuticals SVP sells shares worth $72,633 By Investing.com - Investing.com Australia
Ironwood Pharmaceuticals CFO sells shares worth $21,211 By Investing.com - Investing.com Australia
Ironwood Pharmaceuticals (IRWD) to Release Earnings on Thursday - Defense World
Ironwood Pharmaceuticals’ principal accounting officer sells $21,204 in stock By Investing.com - Investing.com Nigeria
Ironwood Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Could See Prices Soar In The Coming Months - Marketing Sentinel
Financial Health Report: Ironwood Pharmaceuticals Inc (IRWD)’s Ratios Tell a Tale - The Dwinnex
IRWD’s Stock Market Adventure: -61.63% YTD Growth Amidst Volatility - The InvestChronicle
Should You Invest in Ironwood Pharmaceuticals Inc (IRWD) Now? - The News Heater
Ironwood Pharmaceuticals stock falls as it exits S&P SmallCap 600 - MSN
Analysts Say Ironwood Pharmaceuticals Inc Can Reach $7 In 12 Months - Marketing Sentinel
Ironwood Pharmaceuticals Inc [IRWD] Stock trading around $1.94 per share: What’s Next? - The DBT News
Research Analysts Set Expectations for IRWD Q1 Earnings - MarketBeat
IRWD Shares Experience Decline in Value - Knox Daily
Ironwood Pharmaceuticals stock falls as it exits S&P SmallCap 600 By Investing.com - Investing.com Canada
STATE STREET CORP Reduces Stake in Ironwood Pharmaceuticals Inc - GuruFocus.com
Ironwood Pharmaceuticals (NASDAQ:IRWD) Reaches New 1-Year Low Following Analyst Downgrade - MarketBeat
Finanzdaten der Ironwood Pharmaceuticals Inc-Aktie (IRWD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ironwood Pharmaceuticals Inc-Aktie (IRWD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Silver Ronald | Principal Accounting Officer |
Feb 10 '25 |
Sale |
1.76 |
12,048 |
21,204 |
279,655 |
| Shetzline Michael | SVP, CMO, Head-Res&Drug |
Feb 10 '25 |
Sale |
1.76 |
41,269 |
72,633 |
554,007 |
| John Minardo | Chief Legal Officer |
Feb 10 '25 |
Sale |
1.76 |
38,938 |
68,531 |
408,132 |
| Martini Gregory S. | Chief Financial Officer |
Feb 10 '25 |
Sale |
1.76 |
12,052 |
21,212 |
183,810 |
3.23%
3.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):